Cullinan Therapeutics, Inc. 8-K

What Happened
Cullinan Therapeutics, Inc. (CGEM) filed a Current Report on Form 8‑K dated March 10, 2026 to announce its financial results for the year ended December 31, 2025. The company furnished a press release reporting those results as Exhibit 99.1 to the 8‑K. The report was signed by Mary Kay Fenton, Chief Financial Officer.

Key Details

• Item reported: 2.02 — Results of Operations and Financial Condition (annual results announced).
• Filing date: March 10, 2026; reporting period: year ended December 31, 2025.
• Exhibit furnished: 99.1 — press release with the announced results (also included Inline XBRL cover page as Exhibit 104).
• Authorized signatory: Mary Kay Fenton, Chief Financial Officer.

Why It Matters
This 8‑K formally notifies investors that Cullinan has published its full-year 2025 financial results; those results can affect investor views on earnings, revenue trends, cash position and near‑term prospects. The 8‑K itself does not include the numbers — investors should read the attached press release (Exhibit 99.1) and monitor the company’s upcoming annual report (Form 10‑K) for audited financial statements and more detail.